In 2025, PNH News delivered timely coverage of the latest research developments and advances in care related to…
Articles by Margarida Maia, PhD
Vemircopan, a therapy that Alexion, AstraZeneca Rare Disease was developing for paroxysmal nocturnal hemoglobinuria…
An experimental combination of pozelimab and cemdisiran was found to be safe in adults with paroxysmal nocturnal hemoglobinuria (PNH)…
About one in five patients newly diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) in the Nordic countries has a history…
Paroxysmal nocturnal hemoglobinuria (PNH) is being diagnosed more frequently in Italy, and while treatment with complement inhibitors…
Pregnant women with paroxysmal nocturnal hemoglobinuria (PNH) who receive Soliris (eculizumab) have higher chances of their babies surviving compared…
Fabhalta (iptacopan) is now available in Canada, according to its developer Novartis, which noted that it’s the first…
The use of Fabhalta (iptacopan) — approved in the U.S. in December 2023 as a treatment for paroxysmal nocturnal…
Most Chinese adults and adolescents with paroxysmal nocturnal hemoglobinuria (PNH) no longer require blood transfusions after a median of…
Fatigue affects the ability of adults with paroxysmal nocturnal hemoglobinuria (PNH) to perform daily tasks, interact socially, and stay…